Dr. Daniel R. Wahl

Avraham Eisbruch is a Radiation Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Eisbruch is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Throat Cancer, Laryngeal Cancer, Dry Mouth, and Head and Neck Squamous Cell Carcinoma (HNSCC).

Dr. Daniel Chang is a nationally and internationally recognized expert in radiotherapy for GI malignancies. His primary research interest is in advanced radiotherapy techniques, primarily with stereotactic body radiotherapy (SBRT). He has led several studies investigating and establishing the efficacy and safety for SBRT for these diseases for liver and pancreatic tumors. His other research interests include normal tissue tolerances, quality of life after radiotherapy, and combining radiotherapy with targeted agents. In addition, he has a strong interest in the use of radiotherapy, particularly in combination with systemic agents, in patients with metastatic disease. Another area of interest is in health care utilization for patients with metastatic disease and using machine learning and other approaches to optimize care during the end-of-life period.Dr. Chang is interested in developing novel modalities and technologies for delivering radiotherapy. He previously led the FDA trial that led to approval of PET-guided radiotherapy, which in broader terms, is called Biology-guided radiotherapy. In addition, he has experience with MR-guided radiotherapy, and he is interested in exploring the role of particle therapy and heave ion radiotherapy.Dr. Chang received his MD from Wayne State University in 2002 and completed his residency in Radiation Oncology at the University of Florida in Gainesville, Florida in 2007. He then joined the Department of Radiation Oncology at Stanford University from 2007-2022, having previously served as residency program director from 2012-2017 and the Vice Chair of Clinical Operations from 2017-2022 where he was also the Sue and Bob McCollum Professor in Radiation Oncology.Dr. Chang is a member of the American Society of Radiation Oncology (ASTRO), American Radium Society (ARS), and the American Society of Clinical Oncology (ASCO). He serves on the scientific committee for ASTRO, ASCO, and GI ASCO. He has authored or co-authored over 190 peer-reviewed publications for journals including Journal of Clinical Oncology, Journal of the National Cancer Institute, Clinical Cancer Research, Radiology, International Journal of Radiation Oncology, Biology, and Physics, Radiotherapy and Oncology, and Cancer. He served as the senior editor for the GI section of the International Journal of Radiation Oncology, Biology, and Physics from 2013-2017 and is currently on the editorial board for Practical Radiation Oncologysince 2020. He served on the Hepatobiliary Panel for the National Cancer Comprehensive Network (NCCN) guidelines from 2013-2022, helping to shape national guidelines for the work-up, diagnosis, and treatment of patients with hepatobiliary cancers. He is currently the track chair for the GI track for the ASTRO Annual Meeting Scientific Committee. He also serves on the Education Committee for the Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Track for the ASCO annual meeting starting in 2023. Dr. Chang is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Anal Cancer, Squamous Cell Carcinoma of the Anal Canal (SCAC), Pancreaticoduodenectomy, and Pancreatectomy. Dr. Chang is board certified in Radiation Oncology. Dr. Chang is currently accepting new patients.

Dr. Lawrence structured his career to prepare to be a physician scientist by obtaining both an MD and PhD. He initially pursued internal medicine and medical oncology, but ultimately settled on radiation oncology. He is board certified in all 3 areas. He has had an active clinical practice in radiation oncology for 30 years specializing in the treatment of patients with gastrointestinal malignancies and CNS tumors.Dr. Lawrence has focused his research career in two main areas. First, in collaboration with basic scientists he developed a laboratory program in chemotherapeutic radiation sensitizers and, more recently, has studied how to integrate molecularly targeted therapies. He collaborates with basic science faculty interested in translational research to investigate new combinations that can form the basis for rational clinical trials. The second area of focus involves the use of highly conformal radiation therapy in the treatment of brain and gastrointestinal cancers. In particular, he is focusing, in collaboration with medical physicists, radiologists, imaging scientists, and biologists, on the concept of adapting treatment to the individual patient response, assessed both by state-of-the-art imaging and plasma biomarkers.Dr. Lawrence is the author of over 300 peer-reviewed publications, and his work has been continuously supported by the National Cancer Institute for over 20 years. Dr. Lawrence is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Glioma, Glioblastoma, Astrocytoma, Pancreaticoduodenectomy, and Tissue Biopsy. Dr. Lawrence is board certified in Radiation Oncology, Internal Medicine, and Medical Oncology. Dr. Lawrence is currently accepting new patients.

Shruti Jolly MD is an Associate Professor and Associate Chair of Community Practices in the Department of Radiation Oncology at the University of Michigan. She received her undergraduate and medical degrees at Wayne State University as a Presidential Scholar. In 2007, she completed her medical training at William Beaumont Hospital in Royal Oak, Michigan where she served as chief resident and received the RSNA Roentgen Resident Research Award. Dr. Jolly then joined the faculty at the University of Michigan Department of Radiation Oncology. Dr. Jolly directs the treatment of thoracic, gynecologic and endocrine malignancies. She also serves as the director of Brachytherapy, specializing in High Dose Rate (HDR) brachytherapy procedures. Additionally, she is the principal investigator of numerous clinical protocols designed to individualize the radiation therapy of lung and gynecologic cancer patients. Dr. Jolly has authored numerous publications in peer-reviewed journals. As Associate chair of Community Practices, she oversees the standardization and quality of care of patients receiving radiation therapy at the numerous UM Radiation Oncology community practices across the state of Michigan. In addition she also serves as a consultant for the Michigan Radiation Oncology Quality Consortium (MROQC) focused on quality improvement in patients undergoing radiation therapy for breast cancer, lung cancer and bone metastases. Dr. Jolly is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Adrenal Cancer. Dr. Jolly is board certified in Radiation Oncology. Dr. Jolly is currently accepting new patients.

Dr. Mierzwa has 8 years of clinical experience in treatment of head and neck as well as gastrointestinal cancers. Her clinical research interests have included novel chemoradiation regimens for head and neck cancers as well as pancreatic cancer. Specifically, she is currently in collaboration with the Department of Otolaryngology as part of a clinical trial to identify radiographic and serum biomarkers for oropharynx cancer patients who may be eligible for de-escalation of chemoradiation. Dr. Mierzwa is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, Laryngeal Cancer, Dry Mouth, and Pancreaticoduodenectomy. Dr. Mierzwa is board certified in Radiation Oncology. Dr. Mierzwa is currently accepting new patients.

Dr. James Hayman received his medical and master of business administration degrees simultaneously from the University of Chicago in 1991. Following an internship in Evanston, Ill., he began his radiation oncology residency at the Joint Center for Radiation Therapy at Harvard Medical School. He joined the University of Michigan faculty immediately following his residency in 1996 and currently serves as the director of the Clinical Division of the Department of Radiation Oncology. Dr. Hayman's clinical interests include the management of lung, esophageal, breast and central nervous system malignancies. He is also active in the area of health services research. Dr. Hayman is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Melanoma of the Eye, Merkel Cell Carcinoma, and Small Cell Lung Cancer (SCLC). Dr. Hayman is board certified in Radiation Oncology and Hospice & Palliative Med. Dr. Hayman is currently accepting new patients.